Metal Complexes of Biologically Important Ligands, LXXXVI<sup>[1]</sup>

## Organometallic Complexes of Ruthenium(II), Rhodium(III), Iridium(III), and Gold(I) with Cinchona Alkaloids\*

Christopher Missling, Shahram Mihan<sup>[2]</sup>, Kurt Polborn<sup>[2]</sup>, and Wolfgang Beck\*

Institut für Anorganische Chemie der Ludwig-Maximilians-Universität, Meiserstraße 1, 80333 München, Germany

Received October 16, 1995

Key Words: Quinine / Cinchonidine / Quinidine / Chinchonine / Ruthenium complexes / Gold complexes / Rhodium complexes / Iridium complexes

The following chiral organometallic complexes of the cinchona alkaloids quinine (L¹), cinchonidine (L²), quinidine (L³), cinchonine (L⁴) were prepared:  $[(\eta^5-C_5H_5)(Ph_3P)(OC)-Ru(L)]BF_4$  (1:  $L=L^1$ ; 2:  $L=L^2$ ; 3:  $L=L^3$ ),  $ClAuL^1$  (4),  $[(\eta^5-C_5Me_5)(Cl_2)Ir(L)]$  (5:  $L=L^1$ ; 6:  $L=L^2$ ; 7:  $L=L^4$ ),  $[(\eta^5-C_5Me_5)(Cl_2)Rh(L^2)]$  (8),  $[(\eta^6-p\text{-cymene})(Cl_2)Ru(L)]$  (9:  $L=L^1$ ; 10:  $L=L^2$ ; 11:  $L=L^4$ ). In all complexes the tertiary nitrogen

atom of the cinchona alkaloids is bound to the metal. Complexes 5-11 are formed as mixtures of isomers. Elimination of HCl from 10 and 11 gives the neutral N,O-chelate complexes  $(\eta^6\text{-}p\text{-}\text{cymene})(Cl)Ru(L^2-H^+)$  (13) and  $(\eta^6\text{-}p\text{-}\text{cymene})(Cl)Ru(L^4-H^+)$  (14) which were structurally characterized by X-ray diffraction.

Cinchona alkaloids are naturally occurring important drugs and are widely used as chiral auxiliaries in organic synthesis<sup>[3]</sup> and catalysis<sup>[4]</sup>. Of great interest is the pioneering work by Sharpless on the osmium tetroxide-catalyzed asymmetric dihydroxylation of olefins by use of chinchona alkaloid ligands<sup>[4-6]</sup>. To our knowledge only a few metal complexes of cinchona alkaloids have been prepared so far<sup>[7]</sup>. Sharpless et al.<sup>[8]</sup> reported on the structure of the osmium tetroxide complex of (dimethylcarbamoyl)dihydroquinidine. Metal complexes of these alkaloids which have four potential donor groups have to be assumed as intermediates in asymmetric metal-catalyzed reactions where alkaloids are used as adjuvants.

Complexes with one of the two nitrogen-containing fragments of chinchona alkaloids, quinoline [9] and quinuclidine [10] as ligands were reported. We used the Lewis acids  $[(\eta^5-C_5H_5)(Ph_3P)(OC)Ru]^{+[11]}$ ,  $ClAuSMe_2^{[12]}$ , and the chlorine-bridged complexes  $[(\eta^5-C_5Me_5)MCl_2]_2$  (M=Rh, Ir) and  $[(\eta^6-p-cymene)RuCl_2]_2^{[13]}$  as probes for the complexation of the cinchona alkaloids I and II.

## **Results and Discussion**

The in situ [from  $(\eta^5-C_5H_5)(OC)(Ph_3P)RuCl$  and AgBF<sub>4</sub>] prepared organometallic Lewis acid  $(\eta^5-C_5H_5)(OC)-(Ph_3P)Ru^+$  was added to the cinchona alkaloids to give the yellow complexes 1-3.

The gold(I) complex 4 was obtained from Me<sub>2</sub>SAuCl and quinine.

As in DsO<sub>4</sub> complexes of dihydroquinidine<sup>[8]</sup> and quinuclidine<sup>[10]</sup> the alkaloids are coordinated in 1–4 to the quinuclidine nitrogen atom. This follows from the downfield shift of all the <sup>1</sup>H-NMR signals of the hydrogen atoms near the nitrogen atom in comparison to those of the free

quinine cinchonidine	la $R = OCH_3$ Ib $R = H$ lla $R = OCH_3$ IIb $R = H$	
quinidine cinchonine		

ligands. The chemical shifts of the other hydrogen atoms (except 8-H) are very close to those of the free alkaloids.

For several cinchona alkaloids a conformational analysis was carried out by Wynberg and Sharpless<sup>[14]</sup>. From

 $^3J_{8\text{-H},9\text{-H}} = 6.4$  Hz for 1 the dehedral angle 8-H-C-9-C-8-H-9 should be approximately  $100^{\circ[15]}$ . This value suggests a conformation between "open" (60°) and "closed" (150°) in solution<sup>[14a]</sup>. From  $^3J_{8\text{-H},9\text{-H}} = 3.7$  Hz for 4 an open conformation similarly to the free quinine<sup>[14a]</sup> can be assumed.

 $[(\eta^5\text{-}C_5H_5)(Ph_3P)(OC)Ru(L)]BF_4 \qquad \qquad ClAu(cinchonine)$   $\begin{array}{c|c} & & & & & & & & & \\ \hline & 1 - 3 & & & & & & \\ \hline & & & & & & & \\ \hline & 1 & quinine & & & & \\ 2 & chinchonidine & & & & \\ 3 & quinidine & & & & \\ \end{array}$ 

$(\eta^5-C_5Me_5)(Cl)_2M(L)$		$(\eta^6$ -p-cymene)(Cl) <sub>2</sub> Ru(L)		
		5 - 8		9 -11
	M	L	1	L
5	Ir	quinine	9	quinine
6	l Ir	cinchonidine	10	cinchonidine
7	Ir	quinidine	11	cinchonine
8	Rh	cinchonidine		

For the complexes with a chiral metal center 1-3 two  $C_5H_5$  <sup>1</sup>H-NMR signals and two <sup>31</sup>P-NMR signals are observed which we assign to the two diastereoisomers  $S_{Ru}R_N$  and  $R_{Ru}R_N$ . One isomer, presumably  $R_{Ru}R_N$ , predominates.

The IR spectra exhibit a remarkable shift of the  $\nu(OH)$  absorptions of 1-4 in comparison with those of the free alkaloids. This indicates the loss of hydrogen bonds in the metal complexes. The reactions of the chloro-bridged complexes  $[(\eta^6-p\text{-cymene})\text{RuCl}_2]_2$  and  $[(\eta^5-\text{C}_5\text{Me}_5)\text{MCl}_2]_2$  (M = Rh, Ir) with the alkaloids yield the orange, water-soluble complexes 5-11.

A broad intensive IR absorption at  $\tilde{v} = 2500 - 2550 \text{ cm}^{-1}$  of 5-11 is striking. We attribute this band to a N-H<sup>+</sup> vibration<sup>[16]</sup> and therefore we formulate the complexes 5-11 (as shown for 5) with a protonated pyridine ring<sup>[17]</sup>. The vCH absorptions of 5-11 are shifted to higher wavenumbers in comparison with those of the free alkaloids. This was also observed in the IR spectra of piperidine complexes<sup>[18]</sup>.

The  ${}^{1}\text{H-}$  and  ${}^{13}\text{C-NMR}$  spectra of 5-11 show three sets of signals. Two sets (in a ratio 1:1) can be assigned to the

two diastereoisomers of 5-11 which contain a chiral metal center. The third set with weaker signals can be attributed to neutral complexes, as shown for 12. Compound 12 could be separated.

13


During attempts to recrystallize 10 and 11 from  $CH_2Cl_2$  the neutral chelate complexes 13 and 14 were obtained. Complexes 13 and 14 could be prepared directly from [( $\eta^6$ -p-cymene)RuCl<sub>2</sub>]<sub>2</sub> and  $L^2$  in the presence of NaOMe or by deprotonation of 11 with NEt<sub>3</sub>. Characteristic of 13 and 14 is the absence of the IR absorption at  $\tilde{\nu}=2500~\text{cm}^{-1}$ .

## Molecular Structure of 13 and 14

Crystals of 13 and 14 could be obtained from CHCl<sub>3</sub>/pentane. The X-ray structural determinations confirm the existence of the five-membered N,O-chelate (Figure 1, Table 1)<sup>[25]</sup>. The unit cell of 13 (S<sub>Ru</sub>R<sub>N</sub>) and 14 (R<sub>Ru</sub>R<sub>N</sub>) contains only one diastereoisomer. In the crystal of 13<sup>[19]</sup> the cymene ligands are strongly distorted and therefore the data are not presented. The unit cell of 14 contains two independent

molecules which differ in the orientation of the *p*-cymene spectator ligand and the vinyl group.

Figure 1. Structure of one molecule of 14 in the crystal<sup>[a]</sup>



 $^{\rm [a]}$  Selected bond lengths [Å], angles [°] and torsion angles [°]: Ru1-O1 1.977(7), Ru1-Ni 2.180(8), Ru1-Cl1 2.451(3), O1-C30 1.403(11), C30-C10 1.553(14), N1-C16 1.499(11), N1-C14 1.476(12), N1-Cl0 1.520(12); O1-Ru1-Cl1 89.5(2), O1-Ru1-Nl 76.1(3), N1-Ru1-Cl1 87.2(2), C30-O1-Ru1 118.0(6), C14-N1-Ru1 112.8(6), C10-N1-Ru1 106.8(6); O1-Ru1-Nl-C10 -37.8(6), O1-Ru1-N1-C16 -6.4(6), Ru1-O1-C30-C10 -24.8(11), Ru1-O1-C30-C3 -154.2(7), Ru1-N1-C10-C30 35.1(9), Ru1-N1-C10-C11 166.8(7), C16-N1-C10-C30 -84.2(10), O1-C30-C10-N1-10.0(12).

The bond lengths and angles in 13 and 14 and the free alkaloids differ only slightly<sup>[14,20,21]</sup>. The torsional angle O-C-C-N of -78° in the free cinchonidine<sup>[20]</sup> has changed to 8.3 in the complex 13 and from -76.1 in the free cinchonine<sup>[21]</sup> to -10.0 in 14 as a result of complexation. The Ru-O- and Ru-N-bond lengths in 14 [1.977(7) and 2.180(2) Å] are longer than in a comparable bis(chelate) copper(II) complex of the 1,2-aminoalcoholate of 1-ephedrine (1.88 and 2.10 Å)<sup>[22]</sup>. In the Sharpless complex of OsO<sub>4</sub> with (dimethylcarbamoyl)dihydroquinidine as monodentate N-donor an Os-N bond length of 2.49 Å was determined<sup>[8]</sup>.

Generous support by *Deutsche Forschungsgemeinschaft* and *Fonds der Chemischen Industrie* is gratefully acknowledged. We thank Dr. *Martin Schmidt* for valuable help with the X-ray structural studies.

## **Experimental**

The reactions were carried out under dry argon.  $(\eta^5-C_5H_5)Ru-(CO)(PPh_3)Cl^{[11]}$ ,  $[(\eta^5-C_5Me_5)IrCl_2]_2^{[23]}$ ,  $[\eta^5-C_5Me_5)RhCl_2]_2^{[23]}$ ,  $(\eta^6-p-cymene)RuCl_2]_2^{[24]}$  and  $ClAuSMe_2^{[12]}$  were prepared by reported methods. The chinchona alkaloids were used as supplied (Aldrich). AgBF<sub>4</sub> was dried for 2 d in vacuo before use. – NMR: Jeol GSX 270 Q and Jeol EX 400 spectrometers. Selected <sup>1</sup>H-NMR

Table 1. Crystal data and data collection of 14

Empirical formula	C <sub>29</sub> H <sub>35</sub> Cl N <sub>2</sub> O Ru		
Formula weight	1128.22		
Crystal size	0.4 x 0.3 x 0.3 mm		
Crystal color and habit	red Cube		
Crystal system	Orthorhombic		
Space group	P2(1)2(1)2(1)		
Unit cell dimensions	a = 11.087(6)  Å		
	b = 17.616(11) Å		
	c = 26.321(14)  Å		
Volume	5140.7(51) Å <sup>3</sup>		
z	8		
Density (calculated)	1.458 Mg/m <sup>3</sup>		
Absorption coefficient	0.738 mm <sup>-1</sup>		
F(000)	2336		
Diffractometer used	Syntex R3		
Radiation and wavelength	MoK $\alpha$ with $\lambda$ =0.71073 Å		
Scan type	ω		
29 range for data collection	3.10 to 43.08°		
Index ranges	+h, +k, ±l		
Reflections collected	6715		
Independent reflections	5943 (R <sub>int</sub> = 0.0407)		
Solution	Patterson		
Refinement method	Full-matrix Least-Squares on F2		
Hydrogen atoms	riding model, fixed isotropic U		
Weighting scheme	$w^{-1} = \sigma^2 F_0^2 + (0.0426P)^2 + 0.0000P$ where $P = (F_0^2 + 2F_0^2)/3$		
Final R indices [F>4o(F)]	R1 = 0.0517, wR2 = 0.0946		
R indices (all data)	R1 = 0.0871 , wR2 = 0.1096		
Goodness-of-Fit on F <sup>2</sup>	1.004		
Largest difference peak	0.298 eÅ <sup>-3</sup>		
Largest difference hole	-0.289 eÅ- <sup>3</sup>		
Programs used	SHELXTL PLUS 4.11/V		
	SHELXL (Sheldrick 1993)		

signals were assigned as described in ref.<sup>[14]</sup>. For data denoted by asterisk: Distinct signals were not observed; assignment may be reversed. – IR: Nicolet 5 2DX FT-IR spectrophotometer.

(Carbonyl) (n<sup>5</sup>-cyclopentadienyl) (N-quinine) (triphenylphosphane)ruthenium Tetrafluoroborate (1): To a solution of AgBF<sub>4</sub> (29 mg, 0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 ml) was added (η<sup>5</sup>-C<sub>5</sub>H<sub>5</sub>)Ru-(CO)(PPh<sub>3</sub>)Cl (65 mg, 0.13 mmol). The mixture was stirred at room temp. with exclusion of light for 1 h. AgCl was centrifuged off and to the clear, orange solution was added a solution of quinine (52 mg, 0.16 mmol) in CH<sub>2</sub>Cl<sub>2</sub>. After stirring for 1 h the solvent was removed in vacuo and the yellow solid was washed twice with diethyl ether and dried in vacuo. Yield 92 mg (76%), mp 129°C (dec.).  $- {}^{1}H$  NMR (CD<sub>3</sub>CN, 270 MHz):  $\delta = 5.50/5.42$  (6.4 Hz, 9-H), 3.04 (8-H)\*, 3.04 (6-H<sub>a</sub>)\*, 3.45 (6-H<sub>b</sub>)\*, 3.26 (2-H<sub>a</sub>)\*, 2.67  $(2-H_b)^*$ , 3.92/3.91 (s, 3 H, OCH<sub>3</sub>), 5.37/5.16 (s, 5 H, C<sub>5</sub>Me<sub>5</sub>), 6.98-7.56 [m, 15 H,  $(C_6H_5)_3P$ ]. -  $^{31}P$  NMR (CD<sub>3</sub>CN, 109.4MHz):  $\delta = 49.5/48.9 (88:12)$ .  $- C_{44}H_{44}BF_4N_2O_3PRu \cdot 3H_2O_3PRu \cdot 3H_2O_3$ (921.7): calcd. C 57.34, H 5.47, N 3.04; found C 56.95, H 5.23, N 3.13.

(Carbonyl)( $\eta^5$ -cyclopentadienyl)(N-cinchonidine)(triphenylphosphane)ruthenium Tetrafluoroborate (2): Compound 2 was prepared as described for 1 by using  $(\eta^5-C_5H_5)Ru(CO)(PPh_3)Cl$  (118 mg,

0.24 mmol), AgBF<sub>4</sub> (49 mg, 0.25 mmol), and cinchonidine (59 mg, 0.24 mmol). Orange yellow powder, yield 184 mg (87%), mp 134 °C (dec.). - ¹H NMR (CD<sub>3</sub>CN, 270 MHz):  $\delta$  = 3.08 (8-H)\*, 2.61 (6-H<sub>a</sub>)\*, 2.61 (6-H<sub>b</sub>)\*, 3.50 (2-H<sub>a</sub>)\*, 3.08 (2-H<sub>b</sub>)\*, 5.14 (OH), 5.21/5.27 (s, 5 H, C<sub>5</sub>Me<sub>5</sub>), 7.63–6.97 [m, 15 H, (C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>P]. - ³¹P NMR (CDCl<sub>3</sub>, 109.4 MHz):  $\delta$  = 49.4/50.2 (9:1). - C<sub>43</sub>H<sub>42</sub>BF<sub>4</sub>N<sub>2</sub>O<sub>2</sub>PRu 1.5 H<sub>2</sub>O (864.7): calcd. (59.73, H 5.29, N 3.24; found C 59.75, H 4.97, N 3.15.

(Carbonyl) ( $\eta^5$ -cyclopentadienyl) (N-quinidine) (triphenylphosphane) ruthenium Tetrafluoroborate (3): Compound 3 was prepared as described for 1 by using ( $\eta^5$ -C<sub>5</sub>H<sub>5</sub>)Ru(CO)(PPh<sub>3</sub>)Cl (98 mg, 0.20 mmol), AgBF<sub>4</sub> (43 mg, 0.22 mmol), and quinidine (72 mg, 0.22 mmol). Yellow powder, yield 150 mg (85%), mp 135°C (dec.). – <sup>1</sup>H NMR ([D<sub>6</sub>]acetone, 270 MHz): δ = 5.67 (5.2 Hz, 9-H)\*, 3.20 (8-H)\*, 2.28 (6-H<sub>a</sub>)\*, 2.80 (6-H<sub>b</sub>)\*, 3.45 (2-H<sub>a</sub>)\*, 2.98 (2-H<sub>b</sub>)\*, 3.93/3.97 (s, 3 H, OCH<sub>3</sub>), 5.60/5.61 (s, 5 H, C<sub>5</sub>Me<sub>5</sub>), 7.14 – 7.66 (m, 15 H, (C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>P). – <sup>31</sup>P NMR ([D<sub>6</sub>]acetone, 109.4 MHz): δ = 50.4/51.7 (82:18). – C<sub>44</sub>H<sub>44</sub>BF<sub>4</sub>N<sub>2</sub>O<sub>3</sub>PRu · H<sub>2</sub>O (885.7): calcd. C 59.66, H 5.23, N 3.16; found C 59.55, H 5.28, N 3.19.

(Chloro) (N-quinine) gold(I) (4): To a solution of ClAuSMe<sub>2</sub> (74 mg, 0.25 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 ml) a solution of quinine (97 mg, 0.30 mol) in CH<sub>2</sub>Cl<sub>2</sub> was added. After stirring for 2 h at room temp. from the clear colorless solution CH<sub>2</sub>Cl<sub>2</sub> was removed in vacuo. The solid is washed twice with diethyl ether and dried in vacuo to afford a grey white powder which turned violet upon exposure to light. Yield 111 mg (80%), mp 138 °C (dec.). – <sup>1</sup>H NMR ([D<sub>6</sub>]acetone):  $\delta = 5.50$  (3.7 Hz, 9-H), 4.02 (8-H), 3.53–3.62 (6-H<sub>a</sub>)\*, 4.38 (6-H<sub>a</sub>), 2.68 (2-H<sub>a</sub>), 3.53–3.62 (2-H<sub>b</sub>)\*, 6.78 (OH), 4.00 (s, 3 H, OCH<sub>3</sub>). – C<sub>20</sub>H<sub>24</sub>AuClN<sub>2</sub>O<sub>2</sub> (556.8): calcd. C 43.14, H 4.38, N 5.03; found C 42.71, H 4.40, N 4.83.

(*Quinine*) ( $\eta^5$ - $C_5H_5$ ) *IrCl*<sub>2</sub> (**5**): To a solution of [( $\eta^5$ - $C_5Me_5$ )-IrCl<sub>2</sub>]<sub>2</sub> (159 mg, 0.20 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 ml) was added a solution of quinine (265 mg, 0.80 mmol) in CH<sub>2</sub>Cl<sub>2</sub>. After stirring of the reaction mixture for 1 h at room temp. the solvent was removed in vacuo from the clear orange solution. The light orange solid was washed twice with diethyl ether and dried in vacuo. Yield 202 mg (70%), mp 169 °C (dec.). - <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  = 6.19/6.12 (9-H), 3.94/3.28 (8-H), 1.06/0.52 (7-H), 2.53 (6-H<sub>a</sub>)\*, 3.28 (6-H<sub>b</sub>)\*, 4.45/4.30 (2-H<sub>a</sub>), 3.14/2.85 (2-H<sub>b</sub>), 5.88/5.90 (NH), 3.83/3.66 (s, 3 H, OCH<sub>3</sub>), 1.36/1.61 (s, 5 H, C<sub>5</sub>Me<sub>5</sub>), diastereoisomeric ratio 65: 35. - C<sub>30</sub>H<sub>39</sub>Cl<sub>2</sub>IrN<sub>2</sub>O<sub>2</sub> (722.8): calcd. C 49.86, H 5.44, N 3.88; found C 49.23, H 5.54, N 3.80.

(Cinchonidine) ( $\eta^5$ - $C_5Me_5$ ) IrCl<sub>2</sub> ·  $H_2O$  (6): Compound 6 was prepared as described for 5 by using  $[(\eta^5-C_5Me_5)IrCl_2]_2$  (51 mg, 0.06 mmol) and cinchonidine (41 mg, 0.14 mmol). Yield 51 mg (60%), mp 172 °C (dec.). – <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta = 6.22$  (9-H)\*, 3.93/3.39 (8-H), 1.26/0.39 (7-H), 2.52/1.99 (6-H<sub>a</sub>), 3.21 (6-H<sub>b</sub>)\*, 4.43/4.26 (2-H<sub>a</sub>), 2.94 (2-H<sub>b</sub>)\*, 6.00 (NH)\*, 1.38/1.62 (s, 5 H, C<sub>5</sub>Me<sub>5</sub>), diastereoisomeric ratio 55:45. – C<sub>29</sub>H<sub>37</sub>Cl<sub>2</sub>IrN<sub>2</sub>O<sub>2</sub> · H<sub>2</sub>O (710.8): calcd. C 49.01, H 5.53, N 3.94; found C 49.21, H 6.07, N 4.69.

(Cinchonine) ( $\eta^5$ - $C_3Me_5$ ) IrCl<sub>2</sub> ·  $H_2O$  (7): Compound 7 was prepared as described for 5 by using [( $\eta^5$ - $C_5Me_5$ )IrCl<sub>2</sub>]<sub>2</sub> (55 mg, 0.07 mmol) and cinchonine (41 mg, 0.14 mmol). Yield 95 mg (68%), mp 128 °C (dec.). — <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  = 6.48 (9-H)\*, 4.15/4.01 (8-H), 0.87/0.60 (7-H), 3.32 (6-H<sub>a</sub>)\*, 3.37 (6-H<sub>b</sub>)\*, 4.77/4.33 (2-H<sub>a</sub>), 3.03 (2-H<sub>b</sub>)\*, 6.06 (NH)\*, 1.42/1.63 (s, 5 H, C<sub>5</sub>Me<sub>5</sub>), diastereoisomeric ratio 57:43. —  $C_{29}H_{37}Cl_2IrN_2O_2 \cdot 4$  H<sub>2</sub>O (764.8): calcd. C 45.54, H 5.93, N 3.66; found C 45.35, H 2.54, N 3.64.

(Cinchonidine)  $(\eta^5 - C_5 M e_5) RhCl_2 \cdot 0.5 H_2O$  (8): To a solution of  $[(\eta^5 - C_5 M e_5) RhCl_2]_2$  (37.3 mg, 0.06 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was added a

solution of cinchonidine (70.6 mg, 0.24 mmol) in CH<sub>2</sub>Cl<sub>2</sub>. The mixture was stirred for 1.5 h at room temp. during which time it turned light red. The solution was then concentrated in vacuo and the red solid was stirred for 15 h with diethyl ether. The ether phase was decanted and the light orange powder was dried in vacuo. Yield 46 (63%), mp 201 °C (dec.). – <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  = 6.13 (9-H)\*, 3.34 (8-H)\*, 1.22/0.26 (7-H), 2.37/2.30 (6-H<sub>a</sub>), 3.20/3.11 (6-H<sub>b</sub>), 3.89/4.20 (2-H<sub>a</sub>), 2.92 (2-H<sub>b</sub>)\*, 5.79 (NH)\*, 1.55/1.63 (s, 5 H, C<sub>5</sub>Me<sub>5</sub>), diastereoisomeric ratio 61:39. – C<sub>29</sub>H<sub>37</sub>Cl<sub>2</sub>N<sub>2</sub>ORh · 0.5 H<sub>2</sub>O (612.4): calcd. C 56.87, H 6.25, N 4.57; found C 56.50, H 6.14, N 4.65.

 $(η^6$ -p-Cymene) (quinine) RuCl<sub>2</sub> (9): Compound 9 was obtained as described for 5 by using  $[(η^6$ -p-cymene)RuCl<sub>2</sub>]<sub>2</sub> (155 mg, 0.25 mmol) and quinine (239 mg, 0.73 mmol). Dark rcd powder. Yield 240 mg (76%), mp 115 °C (dec.). – <sup>1</sup>H NMR (CDCl<sub>3</sub>, 270 MHz): δ = 6.28/6.20 (9-H), 3.75/2.95 (8-H), 1.48/0.70 (7-H), 2.58/2.30 (6-H<sub>a</sub>), 3.62/2.95 (6-H<sub>b</sub>), 4.23/4.19 (2-H<sub>a</sub>), 3.62/2.95 (2-H<sub>b</sub>), 5.67 (NH)\*, 3.75/3.71 (s, 3 H, OCH<sub>3</sub>), 1.39 and 1.47/1.39 and 1.41 [d, J = 7 Hz, 6 H, CH(CH<sub>3</sub>)<sub>2</sub>], 1.82/2.36 (s, 3 H, ArCH<sub>3</sub>), 3.03/3.07 [sept, 1 H, CH(CH<sub>3</sub>)<sub>2</sub>], 5.65–5.04 (m, 4 H, C<sub>6</sub>H<sub>4</sub>), diastereoisomeric ratio 83:17. – C<sub>30</sub>H<sub>38</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>Ru (630.6): calcd. C 57.14, H 6.07, N 4.44; found C 57.47, H 6.53, N 4.94.

(Cinchonidine) ( $\eta^6$ -p-cymene) RuCl<sub>2</sub> · H<sub>2</sub>O (10): Compound 10 was prepared as described for **5** by using [( $\eta^6$ -p-cymene)RuCl<sub>2</sub>]<sub>2</sub> (74.2 mg, 0.12 mmol) and cinchonidine (71.3 mg, 0.24 mmol). Dark red solid. Yield 105 mg (75%), mp 126 °C (dec.). — <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  = 6.35/5.62 (4.4 Hz, 9-H), 3.75 (8-H)\*, 0.67/0.11 (7-H), 3.25–3.01 (6-H<sub>a</sub>), 3.72/3.57 (6-H<sub>b</sub>), 4.41/4.20 (2-H<sub>a</sub>), 3.25–3.01 (2-H<sub>b</sub>), 1.20 and 1.25/1.27 and 1.35 [d, J = 7 Hz, 6 H, CH(CH<sub>3</sub>)<sub>2</sub>], 2.24/1.78 (s, 3 H, ArCH<sub>3</sub>), 2.88/3.06 [sept, 1 H, CH(CH<sub>3</sub>)<sub>2</sub>], 5.64–4.89 (m, 4 H, C<sub>6</sub>H<sub>4</sub>), diastereoisomeric ratio 55:45. — C<sub>29</sub>H<sub>36</sub>Cl<sub>2</sub>N<sub>2</sub>ORu · H<sub>2</sub>O (618.6): calcd. C 56.31, H 6.19, N 4.53; found C 56.17, H 6.45, N 4.61.

(Cinchonine) ( $\eta^6$ -p-cymene) RuCl<sub>2</sub> · 1.5 H<sub>2</sub>O (11): Compound 11 was prepared as described for 5 by using  $[(\eta^6$ -p-cymene)RuCl<sub>2</sub>]<sub>2</sub> (58.7 mg, 0.09 mmol) and cinchonine (56.4 mg, 0.19 mmol). Dark red solid, yield 107 mg (70%), 119 °C. — <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta = 6.50/5.84$  (9.6 Hz, 9-H), 3.92/3.82 (8-H), 0.80/0.27 (7-H), 3.46 – 3.32 (6-H<sub>a</sub>), 3.20/2.85 (6-H<sub>b</sub>)\*, 4.19/3.61 (2-H<sub>a</sub>), 3.20/2.85 (2-H<sub>b</sub>)\*, 1.15 and 1.19/1.29 and 1.37 [d, J = 7 Hz, 6 H, CH(CH<sub>3</sub>)<sub>2</sub>], 2.26/2.28 (s, 3 H, ArCH<sub>3</sub>), 2.95 – 3.62 [m, 1 H, CH(CH<sub>3</sub>)<sub>2</sub>], 5.02 – 5.48 (m, 4 H, C<sub>6</sub>H<sub>4</sub>), diastereoisomeric ratio 63:37. — C<sub>29</sub>H<sub>36</sub>Cl<sub>2</sub>N<sub>2</sub>ORu·1.5 H<sub>2</sub>O (627.6): calcd. C 55.50, H 6.26, N 4.46; found 5.51, H 6.27, N 4.65.

(*N*-Cinchonidine) ( $\eta^6$ -p-cymene) RuCl<sub>2</sub> (12): To a solution of [( $\eta^6$ -p-cymene)RuCl<sub>2</sub>]<sub>2</sub> (79.6 mg, 0.13 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 ml) was added cinchonidine (79.8 mg, 0.27 mmol). The mixture was stirred for 2 h. After removal of the solvent in vacuo the red solid was stirred with water for 2 h. The orange solid was thoroughly washed with ether. Yield 34 mg (23%), 118 °C (dec.). – <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  = 5.87 (9-H), 4.02 (8-H), 1.31 (7-H), 3.37 (6-H<sub>a</sub>), 3.98 (6-H<sub>b</sub>), 3.50 (2-H<sub>a</sub>), 3.63 (2-H<sub>b</sub>), 5.79 (OH), 1.34 and 1.40 [d, J = 7 Hz, 6 H, CH(CH<sub>3</sub>)<sub>2</sub>], 2.31 (s, 3 H, ArCH<sub>3</sub>), 3.05 [sept, 1 H, CH(CH<sub>3</sub>)<sub>2</sub>], 4.89, 5.18, 5.30, 5.32 (d, J = 6 Hz, 4 H, C<sub>6</sub>H<sub>4</sub>). – C<sub>29</sub>H<sub>36</sub>Cl<sub>2</sub>N<sub>2</sub>ORu (600.6): calcd. C 58.00, H 6.04, N 4.66; found C 58.49, H 6.50, N 5.00.

 $(N.O\text{-}Cinchonidine-H^+)$   $(\eta^6\text{-}p\text{-}cymene)$  RuCl (13): To a solution of  $[(\eta^6\text{-}p\text{-}cymene)$   $RuCl_2]_2$  in methanol (5 ml) were added cinchonidine (47.9 mg, 0.16 mmol) and a solution of NaOMe in methanol (0.16 mmol NaOMe). After stirring for 1 h the solvent was evaporated in vacuo from the clear, orange solution. The solid was stirred for 10 min with  $CH_2Cl_2 \cdot NaCl$  was centrifuged off. The  $CH_2Cl_2$ 

solution was evaporated to dryness and the orange solid was washed with pentane and dried in vacuo. Yield 64 mg (68%) mp. 116°C (dec.). – <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta = 6.10 (9-H)^*$ , 3.50/4.30 (8-H)\*, 1.20/1.30 (7-H), 2.40/2.54 (6-H<sub>a</sub>), 3.52/4.31 (6-H<sub>b</sub>)\*, 3.52/4.31 (2-H<sub>a</sub>)\*, 3.20/3.28 (2-H<sub>b</sub>), 6.10 (NH), 1.40 and 1.41/1.32 and 1.44 [d, J = 7 Hz, 6 H, CH(CH<sub>3</sub>)<sub>2</sub>], 2.27/2.23 (s, 3 H, ArCH<sub>3</sub>), 2.94  $[m, 1 H, CH(CH_3)_2], 4.81-5.32 (m, 4 H, C_6H_4), diastereoisomeric$ ratio  $57:43. - C_{29}H_{35}CIN_2ORu \cdot H_2O$  (582.2): calcd. C 59.83, H 6.41. N 4.81: found C 59.44. H 6.51. N 4.86.

 $(N, O\text{-}Cinchonine - H^+)(\eta^6\text{-}p\text{-}cymene)RuCl$  (14): To a solution of 11a, b (40 mg, 0.06 mmol) in methanol (5 ml) NEt<sub>3</sub> (6 µl, 0.2 mmol) was added. The red solution was stirred for 30 min at room temp, and evaporated to dryness. The solid was four times extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 ml). The solvent was evaporated in vacuo from the combined extracts to give a red powder. Yield 27 mg (80%), mp. 104°C (dec.). - C<sub>29</sub>H<sub>35</sub>ClN<sub>2</sub>ORu · 2 H<sub>2</sub>O (600.2): calcd. C 58.04, H 6.55, N 4.67; found C 58.30, H 6.40, N 4.88.

- ganometallics 1988, 7, 2250-2252; G. A. Stark, A. M. Arif, J.
- A. Gladysz, *ibid* 1994, 13, 4523-4530.
   E.g.: W. P. Griffith, A. C. Skapski, K. A. Woode, M. J. Wright, *Inorg. Chim. Acta* 1978, 31, L413-L414.
- [11] J. W. Faller, Y. Ma, C. J. Smart, M. J. DiVerdi, J. Organomet. Chem. 1991, 420, 237-252; R. J. Kulawiec, J. W. Faller, R. H. Crabtree, Organometallics 1990, 9, 745-755; J. Milke, C. ling, K. Sünkel, W. Beck, J. Organomet. Chem. 1993, 445, 219-227.
- [12] F. Bonati, G. Minghetti, Gazz. Chim. Ital. 1973, 103, 373-386. [13] [13a] M. A. Bennett, M. I. Bruce, T. W. Matheson, R. P. Hughes, G. J. Leigh, R. L. Richards in Comprehensive Organometallic Chemistry (Eds.: G. Wilkinson, F. G. A. Stone, E. W. Abel), Pergamon Press, Oxfort, **1982** vol. 4, p. 796; vol. 5, p. 368, 599, 604; <sup>[13b]</sup> W. S. Sheldrick, H. S. Hagen-Eckhard, S. Heeb, *Inorg. Chim. Acta* **1993**, 206, 15–21; W. S. Sheldrick, S. Heeb, *Inorg. Chim. Acta* **1990**, 168, 93–100; <sup>[13c]</sup> R. Krämer, M. Maurus, R. Bergs, K. Polborn, K. Sünkel, B. Wagner, W. Beck, *Chem. Ber.* **1993**, *126*, 1969–1980.

  [14] [14a] G. D. H. Dijkstra, R. M. Kellogg, H. Wynberg, J. S.
- Svendsen, I. Marko, K. B. Sharpless, J. Am. Chem. Soc. 1989, 111, 8069-8076; G. D. H. Dijkstra, R. M. Kellogg, H. Wynberg, J. Org. Chem. 1990, 55, 6121-6131; [146] G. D. H. Dijkstra, R. M. Kellogg, H. Wynberg, Red. Trav. Chim. Pays-Pas 1989, 108, 195; Y. Yaunka, S. J. Superstine, E. Superstine, J. Pharm. Sci. 1979, 68, 1400; E. Wenkert, J. S. Bindra, C.-J. Chang, D. W. Cochen, E. M. Schell, 4-c. Chang, D. W. Chang Chang, D. W. Cochran, F. M. Schell, Acc. Chem. Res. 1974, 7, 46-51; G. G. Lyle, L. K. Keefer, *Tetrahedron* **1967**, 23, 3253-3263; C. G. Moreland, A. Philip, F. I. Carroll, *J. Org.*
- Chem. 1974, 39, 2413-2416. C. A. G. Haasnoot, F. A. A. M. dc Leeuw, C. Altona, *Tetra*hedron 1980, 36, 2387
- [16] M. Hesse, H. Meier, B. Zee, Spektroskopische Methoden in der organischen Chemie, Thieme, Stuttgart, 1987.
- [17] We thank Dr. K. Severin, München, for this suggestion.
- [18] N. N. Greenwood, K. Wade, J. Chem. Soc. 1960, 1130-1141.
- [19] C. Missling, Dissertation, Universität München, 1994.
- [20] B. J. Oleksyn, Acta Crystallogr., Sect. B: Struct. Crystallogr., Cryst. Chem. 1982, B38, 1832–1834.
- [21] B. Oleksyn, L. Lebioda, Acta Crystallogr., Sect. B: Struct. Crystallogr., Cryst. Chem. 1979, B35, 440-444.
- Y. Amano, K. Osaki, T. Watanabé, Bull. Chem. Soc. Jpn. 1964,
- 37, 1363-1372.
  [23] C. White, A. Yates, P. M. Maitlis, *Inorg. Synth.* **1992**, 29,
- [24] M. A. Bennett, T. N. Huang, T. W. Matheson, A. K. Smith, Inorg. Synth. 1982, 21, 74-78.
- [25] Futher details of the crystal structure investigation are available on request from Fachinformationszentrum mbH, D-76344 Eggenstein-Leopoldshafen, on quoting the depository number CSD-59152 the names of the authors, and the journal citation.

Dedicated to Dr. Janina Altman on the occasion of her 65th

Part 85: R. Lampeka, S. Mihan, W. Beck, Z. Naturforsch., in

X-ray structural studies.

<sup>[3]</sup> E.g.: R. M. Lequan, M. Lequan, Tetrahedron Lett. 1981, 22, 1323-1326; R. M. Lequan, M. Lequan, J. Organomet. Chem. 1982, 226, 35-40; O. Cervinka, J. Fusek, Collect. Czech. Chem. Commun. 1973, 38, 441-446; O. Cervinka, O. Kriz, ibid. 1973, 38, 294-297; W. A. H. Vermeer, A. Fulford, P. Johnston, P. B. Wells, J. Chem. Soc., Chem. Commun. 1993, 1053-1054.

M. G. Finn, K. B. Sharpless in Asymmetric Synthes (Ed.: J. H. D. Morrison), Academic Press 1985, 5, 259; D. J. Berriesford, C. Bolm, K. B. Sharpless, *Angew. Chem.* **1995**, *107*, 1159–1171; Angew. Chem. Int. Ed. Engl. **1995**, *34*, 1050–1064.

H. C. Kolb, M. S. VanNieuwenhze, K. B. Sharpless, Chem. Rev.

<sup>1994, 94, 2483-2547</sup> and references therein.

[6] H. C. Kolb, P. G. Andersson, K. B. Sharpless, *J. Am. Chem.* Soc. 1994, 116, 1278-1291; P.-O. Norrby, H. C. Kolb, K. B. Sharpless, *ibid.* **1994**, 116, 8470–8478 and references therein.

E. Vascantanu, V. Jurga, Al. I. Cuza, Iasi Sect. 1958, 14, 201; Z. Foldi, T. Foldi, A. Foldi, Acta Chim. Acad. Sci. Hung. 1958, 16, 185 (Chem. Abstr. 1959, 53, 5945); J. M. Tsangaris, G. T. Baxevanidis, Z. Naturforsch., B: Anorg. Chem., Org. Chem. 1974, 298, 532-537; J. M. Tsangaris, T. A. Kabanos, Monatsh. Chem. 1982, 113, 1393-1398.

J. S. Svendsen, I. Marko, E. N. Jacobsen, C. P. Rao, S. Bott, K. B. Sharpless, J. Org. Chem. 1989, 54, 2263-2264.

<sup>[9]</sup> E.g.: R. H. Fish, H.-S. Kim, J. E. Babin, R. D. Adams, Or-